Doug Morgan, MD
Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer enter
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Doug Morgan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02794428 · Chemoprevention of Gastric CarcinogenesisVanderbilt-Ingram Cancer Center · completed · Gastric Cancer, Gastric Intestinal Metaplasia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Targeted chemoprevention of gastric carcinogenesis in high risk populationsR01CA190612 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Douglas Morgan, Keith T. Wilson · fiscal years 2014 to 2018Named on NCT02794428
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.